Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ARGX
BUYargenx SE · Healthcare · Netherlands · $57.1B · Avg Vol: $293M/d
70
StockRankGet insider-trade alerts
Q
69
V
16
M
79
P/E (TTM)
31.7x
ROE
23.6%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
argenx SE is a commercial-stage biotechnology company developing differentiated antibody therapeutics for severe autoimmune diseases and cancer, notably with its approved product VYVGART. The company's competitive edge stems from its proprietary SIMPLE Antibody™ platform and expertise in FcRn biology, enabling a deep pipeline targeting significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 497.3M | 410.7M | 1.2B | 2.2B | 4.2B | 70.0% | 5.3B | 6.0B | 7.4B | 33.7% |
| EPS | -7.99 | -13.05 | -5.16 | 13.92 | 21.08 | 51.4% | 26.21 | 30.80 | — | 46.1% |
| Shares | 51.7M | 55.4M | 59.2M | 60.8M | 61.9M | +19.8% | 62.2M | — | — | — |
| Debt | 11.5M | 12.4M | 20.0M | 39.1M | 47.2M | 42.4% | 47.0M | — | — | — |
| Equity | 2.5B | 2.8B | 4.1B | 5.5B | 7.3B | 30.4% | — | — | — | — |
| Op CF | -606.8M | -862.8M | -420.3M | -82.7M | 685.2M | — | 974.2M | — | — | — |
| Inv CF | -347.1M | -461.2M | 308.2M | -717.6M | 984.0M | — | — | — | — | — |
| Fin CF | 1.1B | 843.8M | 1.3B | 279.8M | 233.0M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-2.7%
SMA 50SMA 200
Close
$853.82
RSI (14)
45.7
52W High
$953.58
From 52W High
0.9%
SCORE BREAKDOWN
Quality
69
ROIC
17.4%89.5
ROE
23.6%86.6
GP/Assets
36.2%69.5
Op. Margin
32.0%91.7
FCF/Assets
—N/A
Piotroski
550.0
Int. Cover
50.0x88.8
D/E Ratio
0.01x87.1
Current Ratio
5.12xN/A
Value
16
P/E (TTM)
31.7x29.0
EV/EBITDA
824.5x0.5
P/FCF
—N/A
P/B
154.3x0.4
P/S
9.7x25.2
Div Yield
—N/A
Momentum
79
52W High %
90%90.0
RS 6M
-7%67.9
SMA 50/200
1.05x74.4
EPS Rev 4W
+1.8%87.0
EPS Rev 12W
+12.0%87.4
EPS Improve
+49%63.3
Q Growth
92%86.9
FUNDAMENTALS
Market Cap
$57.1B
P/E (Forward)
21.2x
Gross Margin
59.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARGX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ARGX | argenx SE(you) | $57.1B | 70 | BUY |
| UCB.BR | UCB SA | $56.0B | 64 | HOLD |
| RPRX | Royalty Pharma plc | $33.9B | 70 | BUY |
| ONC | BeOne Medicines AG | $33.8B | 70 | BUY |
| REGN.MX | Regeneron Pharmaceuticals, Inc. | $64.9B | 78 | BUY |
| 0QNO.L | Lonza Group AG | $47.0B | 61 | HOLD |
| 0HAV.L | Agilent Technologies, Inc. | $36.7B | 60 | HOLD |
| VRTX | Vertex Pharmaceuticals Incorporated | $121.2B | 76 | BUY |
| 207940.KS | Samsung Biologics Co.,Ltd. | $40.5B | 55 | HOLD |
| 0JDM.L | IQVIA Holdings Inc. | $33.9B | 57 | HOLD |
Peer medians: ROE 2.1% · P/E 23.5x · Gross margin 50.2%